APSR2026-144

 
Regular
Submitted
Poster Presentation
 
AP14-005
P24
 
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Hengxing Gao - the First Affiliated Hospital of Xi'an Jiaotong University Department of Respiratory and Critical Care Medicine, Xi'an, Shaanxi Province, China
Xiaoning Wang - the First Affiliated Hospital of Xi'an Jiaotong University Department of Respiratory and Critical Care Medicine, Xi'an, Shaanxi Province, China
Mingwei Chen * the First Affiliated Hospital of Xi'an Jiaotong University Department of Respiratory and Critical Care Medicine, Xi'an, Shaanxi Province, China
-
-
-
-
-
-
-
-
-
-
-
-
Presenting Author Details
Mingwei
Chen
chenmw36@163.com
+86+86+86+8613088988001
61-70
China
Original Research
Mechanism of MiR-135a-5p/STAT6 in Inhibiting Non-small Cell Lung Cancer Progression and Regulating Tumor-associated Macrophages Polarization
Maximum 25 words
Abstract Content

The mechanisms underlying the regulation of EMT in NSCLC by miRNAs, and its subsequent impact on the polarization of M2-like TAMs and the expression of Arg1, remain unclear. This study aims to explore the aforementioned mechanisms.

1. RT-qPCR and Western blot were employed to verify the regulation of STAT6 expression and activity by miR-135a-5p.  

2. Western blot was used to detect the expression of proteins in the STAT6/GATA3/IL-4 signaling pathway. ELISA was performed to measure IL-4, IL-10, VEGF-A, and MMP-9.  

3. lung cancer model in nude mice was established, with miR-135a-5p agomir (mimic) and negative controls injected via tail vein.  IHC and IF were used to detect the expression of STAT6, GATA3, IL-4, EMT markers, and Arg1.

1. Serum Arg1 levels were significantly elevated in NSCLC patients compared to the control group (2.98 vs 0.87 ng/mL, P<0.001). The sensitivity of Arg1 for NSCLC diagnosis was 83.3%, which increased to 88.1%. The Arg1 expression was associated with overall survival, tumor size, presence or absence of metastasis, and Ki-67 expression in patients.  

2. STAT6 regulated GATA3-induced IL-4 secretion. MiR-135a-5p was downregulated in NSCLC cells and tissues, and was correlated with shorter overall survival, larger tumor volume, and distant metastasis.  

3. MiR-135a-5p inhibited the expression and activity of STAT6. Inhibition of STAT6 could partially reverse the promoting effects of miR-135a-5p knockdown on NSCLC cell proliferation and metastasis.  

4. MiR-135a-5p inhibited STAT6 expression and blocked the cascade reaction of the STAT6/GATA3/IL-4 signaling pathway, reducing IL-4 secretion in NSCLC cells (P<0.001).   

5. IHC and IF demonstrated that overexpression of miR-135a-5p suppressed the expression of STAT6, GATA3, and IL-4 in tumor tissues, and inhibited the expression of Arg1 in M2-like TAMs and their infiltration in the peritumoral stroma.

1. Serum levels of Arg1 are significantly elevated in NSCLC patients, holding promise as one of the novel biomarkers for NSCLC diagnosis and prognosis assessment.   

2. As a marker of M2-like TAMs polarization, Arg1 expression is potentially regulated by the STAT6/GATA3/IL-4 signaling pathway in NSCLC cells.   

3. MiR-135a-5p/STAT6 inhibits EMT in NSCLC, and regulates GATA3-induced IL-4 secretion, and Arg1 expression of M2-like TAMs, and attenuating their tumor-promoting functions.

 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
NSCLC, MiR-135a-5p, STAT6
maximum 3 keywords and no abbreviations, separated by commas
NO
366